• About
  • Policies
  • What is openaccess
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Expression of CK-19 and CEA mRNA in peripheral blood of gastric cancer patients

      Thumbnail
      View / Download
      134.8 Kb
      Author
      Kutun, S.
      Celik, A.
      Cem Kockar, M.
      Erkorkmaz, U.
      Eroǧlu, A.
      Cetin, A.
      Erkosar, B.
      Yakicier, C.
      Date
      2010
      Source Title
      Experimental Oncology
      Print ISSN
      18129269
      Volume
      32
      Issue
      4
      Pages
      263 - 268
      Language
      English
      Type
      Article
      Item Usage Stats
      85
      views
      30
      downloads
      Abstract
      Aim: To investigate the clinical and pathological relevance of detection of circulating tumor cells (CTC) in the peripheral blood of gastric carcinoma patients before operation. Patients and Methods: Fifty patients with gastric adenocarcinoma were analysed prospectively. Patients were divided into two groups according to the extent of the tumor. Group I (unresectable) consisted of 22, and group II (resectable) consisted of 28 patients. Peripheral blood samples were collected pre-operatively from all 50 patients as well as from ten healthy controls and analyzed for carcinoembryonic antigen (CEA) and cytokeratin-19 (CK-19) messenger ribonucleic acids (mRNAs). Tumor localisation, stage, presence of signet cell formation, nodal metastases, serousal and lymphovascular invasion were recorded for all patients. Results: Expression of CK-19 was detected in 24 (48%), and CEA in 10 (20%) cases. Nine patients (40%) in group I and 15 (53.6%) in group II were positive for CK-19 expression. CEA expression was more frequent among group I patients (6 vs. 4 cases). There was no significant difference between the groups in the expression of CK-19 and CEA mRNA, tumor localisation, presence of signet formation, and presence and extent of nodal metastases. Patients with major vascular invasion (MVI) expressed significantly higher levels of CTC mRNA compared to those without MVI (p = 0.023 for CEA, and p = 0.009 for CK-19). The median 1 and 2-year survival was 9.5 and 10.5 months for group I, and 20 and 28.5 months for group II, respectively (p = 0.001). The mean survival was 6.7 months for patients with MVI, and 30.2 months for those without MVI (p = 0.0001). Conclusions: High levels of CTCs were observed in patients with MVI invasion, rather than other causes of unresectability. It can be suggested that expression of both CEA and CK-19 in the peripheral blood of gastric cancer patients are strong predictors of MVI and significantly worse survival rates. Copyright © Experimental Oncology, 2010.
      Keywords
      Carcinoembryonic antigen
      Cytokeratin-19
      Gastric carcinoma
      Micrometastases
      mRNA
      Vascular invasion
      carcinoembryonic antigen
      cytokeratin 19
      fluorouracil
      folinic acid
      messenger RNA
      adult
      aged
      antigen expression
      article
      cancer invasion
      cancer localization
      cancer patient
      cancer surgery
      cancer survival
      cell
      controlled study
      disease severity
      female
      human
      human cell
      human tissue
      lymph node metastasis
      lymph vessel
      major clinical study
      male
      metastasis
      multiple cycle treatment
      predictor variable
      prospective study
      signet cell
      stomach adenocarcinoma
      stomach carcinoma
      survival rate
      survival time
      tumor cell
      tumor localization
      Adenocarcinoma
      Adult
      Aged
      Aged, 80 and over
      Carcinoembryonic Antigen
      Female
      Humans
      Kaplan-Meier Estimate
      Keratin-19
      Male
      Middle Aged
      Neoplastic Cells, Circulating
      Prognosis
      Reverse Transcriptase Polymerase Chain Reaction
      RNA, Messenger
      Stomach Neoplasms
      Tumor Markers, Biological
      Permalink
      http://hdl.handle.net/11693/22085
      Collections
      • Department of Molecular Biology and Genetics 426
      Show full item record

      Related items

      Showing items related by title, author, creator and subject.

      • Thumbnail

        TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT 

        Hill, R.; Madureira, P. A.; Ferreira, B.; Baptista, I.; Machado, S.; Colaço, L.; Dos Santos, M.; Liu, N.; Dopazo, A.; Ugurel, S.; Adrienn, A.; Kiss-Toth, E.; Isbilen, M.; Gure, A. O.; Link, W. (Nature Publishing Group, 2017)
        Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment failure for many cancer patients. The identification of molecular mechanisms involved in drug resistance or sensitization is imperative. ...
      • Thumbnail

        The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelialmesenchymal transition in breast cancer 

        Raza, U.; Saatci, O.; Uhlmann, S.; Ansari, S. A.; Eyüpoglu, E.; Yurdusev, E.; Mutlu, M.; Ersan, P. G.; Altundağ, M. K.; Zhang, J. D.; Dogan, H. T.; Güler, G.; Şahin, Ö. (Impact Journals LLC, 2016)
        Tumor cells develop drug resistance which leads to recurrence and distant metastasis. MicroRNAs are key regulators of tumor pathogenesis; however, little is known whether they can sensitize cells and block metastasis ...
      • Thumbnail

        Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade 

        Lotem, M.; Merims, S.; Frank, S.; Hamburger, T.; Nissan, A.; Kadouri, L.; Cohen, J.; Straussman, R.; Eisenberg, G.; Frankenburg, S.; Carmon, E.; Alaiyan, B.; Shneibaum, S.; Ayyildiz, Z. O.; Isbilen, M.; Senses, K. M.; Ron, I.; Steinberg, H.; Smith, Y.; Shiloni, E.; Gure, A. O.; Peretz, T. (Hindawi Limited, 2016)
        Background. There is not yet an agreed adjuvant treatment for melanoma patients with American Joint Committee on Cancer stages III B and C. We report administration of an autologous melanoma vaccine to prevent disease ...

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartments

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 1771
      Copyright © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy